Jupiter Neurosciences Receives Nasdaq Delisting Notice; Appeals

What Happened

• On August 27, 2026, Jupiter Neurosciences, Inc. (JUNS) received a written notice from Nasdaq’s Listing Qualifications Staff notifying the company that Nasdaq had determined to delist JUNS common stock from The Nasdaq Capital Market for failure to meet the minimum market value requirement under Nasdaq Listing Rule 5550(b)(2).
• Nasdaq previously notified the company on February 26, 2026 that the market value of listed securities had been below the $35,000,000 minimum for 30 consecutive trading days and gave JUNS 180 calendar days (through August 25, 2026) to regain compliance; Nasdaq’s August 27 notice states the company did not regain compliance with that rule or any alternative continued listing requirement.
• JUNS intends to appeal the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel and expects the hearing request to stay further action pending the Panel’s decision, but the company acknowledged there is no assurance the appeal or any request for continued listing will be granted.
• Separately, also on August 27, 2026, Nasdaq staff notified JUNS that the company had regained compliance with the minimum $1.00 bid-price requirement (Nasdaq Listing Rule 5550(a)(2)) based on 10 consecutive business days of closing bids from August 13–26, 2026; that matter is closed.

Key Details

• Delisting notice date: August 27, 2026; prior notice of market-value deficiency: February 26, 2026.
• Minimum market value threshold missed: $35,000,000 (Nasdaq Rule 5550(b)(2)); 180-day cure period expired August 25, 2026.
• Bid-price compliance regained: 10 consecutive business days (Aug 13–26, 2026), satisfying Nasdaq Rule 5550(a)(2).
• Company action: intends to request a hearing before the Nasdaq Hearings Panel and is considering options to regain listing compliance.

Why It Matters

• A Nasdaq delisting determination is material because if upheld it could remove JUNS from The Nasdaq Capital Market, reduce liquidity, limit investor access, and make capital raising more difficult.
• The company’s appeal may pause delisting while the Panel reviews the case, but there is no guarantee of a successful outcome.
• Regaining the $1.00 bid-price requirement removes one immediate compliance issue, but the company still faces the market-value deficiency that prompted the delisting notice; investors should monitor updates, the outcome of the hearing, and any actions JUNS takes to restore compliance.